Another drug maker is cutting the price of insulin
Sanofi announcing its dropping the prices of one of its drugs by 78%
Atlantis as the company's most widely prescribed insulin in the country.
The company also says it is setting a $35
a month cap for patients with private insurance.
The move follows similar ones by Eli Lilly and Novo Nordisk this month.